Immunotherapy before surgery: a new hope for oral cancer patients
NCT ID NCT03021993
Summary
This study tested whether giving the immunotherapy drug nivolumab to patients before their oral cancer surgery could improve outcomes. Seventeen adults with advanced oral cavity cancer received the drug prior to their scheduled operation. Researchers measured how the tumor responded to the drug and looked for changes in the patients' immune systems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL CAVITY SCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
Conditions
Explore the condition pages connected to this study.